Per Norlén
Chief Executive Officer chez WNTRESEARCH AB
Fortune : - $ au 31/03/2024
Profil
Per Norlén is currently the Chief Executive Officer at Wntresearch AB.
He is also a Director at Atlas Therapeutics AB and an Associate Professor at the University of Lund.
Previously, he served as the Chief Executive Officer at Alligator Bioscience AB from 2018 to 2021 and as the Chief Executive Officer at Targinta AB from 2021 to 2022.
He was also a Director at A Bioscience Incentive AB and a Senior Clinical Pharmacology Physician at AstraZeneca AB.
Additionally, he served as the Chief Medical Officer at Xintela AB from 2021 to 2022 and as the Chief Executive & Medical Officer at Evaxion Biotech A in 2023.
Dr. Norlén holds a doctorate degree from the University of Lund.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
EVAXION BIOTECH A/S
-.--% | 31/03/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Per Norlén
| Sociétés | Poste | Début |
|---|---|---|
| WNTRESEARCH AB | Chief Executive Officer | 10/01/2024 |
| University of Lund | Corporate Officer/Principal | - |
Atlas Therapeutics AB
 Atlas Therapeutics AB Pharmaceuticals: MajorHealth Technology Part of Alligator Bioscience AB, Atlas Therapeutics AB develops and manufactures antibody drugs. The private company is based in Stockholm, Sweden. Atlas Therapeutics was acquired by Alligator Bioscience AB on October 18, 2013. | Director/Board Member | - |
Anciens postes connus de Per Norlén
| Sociétés | Poste | Fin |
|---|---|---|
| EVAXION BIOTECH A/S | Chief Executive Officer | 29/08/2023 |
Targinta AB
 Targinta AB BiotechnologyHealth Technology Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The private company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022. | Chief Executive Officer | 01/09/2022 |
| XINTELA AB | Chief Tech/Sci/R&D Officer | 01/09/2022 |
| ALLIGATOR BIOSCIENCE AB | Chief Executive Officer | 18/03/2021 |
| A Bioscience Incentive AB | Chairman | - |
Formation de Per Norlén
| University of Lund | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| ALLIGATOR BIOSCIENCE AB | Health Technology |
| WNTRESEARCH AB | Health Technology |
| XINTELA AB | Health Technology |
| EVAXION BIOTECH A/S | Health Technology |
| Entreprise privées | 4 |
|---|---|
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
Atlas Therapeutics AB
Atlas Therapeutics AB Pharmaceuticals: MajorHealth Technology Part of Alligator Bioscience AB, Atlas Therapeutics AB develops and manufactures antibody drugs. The private company is based in Stockholm, Sweden. Atlas Therapeutics was acquired by Alligator Bioscience AB on October 18, 2013. | Health Technology |
| A Bioscience Incentive AB | |
Targinta AB
Targinta AB BiotechnologyHealth Technology Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The private company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022. | Health Technology |
